Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma.

IF 2.8 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI:10.1097/CCO.0000000000001133

Thibault Gauduchon, Eve Marie Neidhardt, Jerome Fayette

{"title":"Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma.","authors":"Thibault Gauduchon, Eve Marie Neidhardt, Jerome Fayette","doi":"10.1097/CCO.0000000000001133","DOIUrl":null,"url":null,"abstract":"Purpose of review: Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains a significant therapeutic challenge due to its biological complexity and clinical heterogeneity. This review addresses the relevance of exploring novel therapeutic approaches, particularly in light of recent advances and the persistent unmet needs in patient outcomes.Recent findings: Recent phase II and III clinical trials have highlighted promising strategies, including combinations of immunotherapy with targeted therapies, antibody-drug conjugates (ADCs), HPV vaccines, dual immunotherapy approaches, and therapies targeting the tumor microenvironment. These innovations represent emerging directions to overcome resistance mechanisms and improve treatment efficacy.Summary: The findings suggest that integrating innovative strategies such as ADCs, immunotherapy combinations, and tumor microenvironment-targeting therapies may significantly enhance clinical outcomes for patients with R/M HNSCC. Further research is essential to refine these approaches and optimize their application in clinical practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"175-183"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains a significant therapeutic challenge due to its biological complexity and clinical heterogeneity. This review addresses the relevance of exploring novel therapeutic approaches, particularly in light of recent advances and the persistent unmet needs in patient outcomes.

Recent findings: Recent phase II and III clinical trials have highlighted promising strategies, including combinations of immunotherapy with targeted therapies, antibody-drug conjugates (ADCs), HPV vaccines, dual immunotherapy approaches, and therapies targeting the tumor microenvironment. These innovations represent emerging directions to overcome resistance mechanisms and improve treatment efficacy.

Summary: The findings suggest that integrating innovative strategies such as ADCs, immunotherapy combinations, and tumor microenvironment-targeting therapies may significantly enhance clinical outcomes for patients with R/M HNSCC. Further research is essential to refine these approaches and optimize their application in clinical practice.

查看原文本刊更多论文

复发性或转移性头颈部鳞状细胞癌的治疗前景。

回顾目的：复发性或转移性头颈部鳞状细胞癌（R/M HNSCC）由于其生物学复杂性和临床异质性仍然是一个重大的治疗挑战。这篇综述探讨了探索新治疗方法的相关性，特别是考虑到最近的进展和患者预后持续未满足的需求。最近的发现：最近的II期和III期临床试验强调了有希望的策略，包括免疫治疗与靶向治疗的组合、抗体-药物偶联物（adc）、HPV疫苗、双重免疫治疗方法和针对肿瘤微环境的治疗。这些创新代表了克服耐药机制和提高治疗效果的新兴方向。摘要：研究结果表明，整合adc、免疫治疗组合和肿瘤微环境靶向治疗等创新策略可能显著提高R/M型HNSCC患者的临床预后。进一步的研究是必要的，以完善这些方法和优化其在临床实践中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.